CN102741227B - 芳基苄基胺化合物 - Google Patents
芳基苄基胺化合物 Download PDFInfo
- Publication number
- CN102741227B CN102741227B CN201180008071.0A CN201180008071A CN102741227B CN 102741227 B CN102741227 B CN 102741227B CN 201180008071 A CN201180008071 A CN 201180008071A CN 102741227 B CN102741227 B CN 102741227B
- Authority
- CN
- China
- Prior art keywords
- methyl
- chloro
- phenyl
- benzyl
- formic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc1c(*)c(*)cc(C(*)N)c1 Chemical compound Cc1c(*)c(*)cc(C(*)N)c1 0.000 description 12
- RFSPCEJTXAVJPJ-HXUWFJFHSA-N CC[C@H](c(cc1C)cc(C)c1Cl)Nc1ccc(C)c(CNCCC(O)=O)c1 Chemical compound CC[C@H](c(cc1C)cc(C)c1Cl)Nc1ccc(C)c(CNCCC(O)=O)c1 RFSPCEJTXAVJPJ-HXUWFJFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30060710P | 2010-02-02 | 2010-02-02 | |
| US61/300,607 | 2010-02-02 | ||
| PCT/EP2011/051296 WO2011095452A1 (en) | 2010-02-02 | 2011-01-31 | Aryl benzylamine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102741227A CN102741227A (zh) | 2012-10-17 |
| CN102741227B true CN102741227B (zh) | 2014-07-30 |
Family
ID=43734141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180008071.0A Expired - Fee Related CN102741227B (zh) | 2010-02-02 | 2011-01-31 | 芳基苄基胺化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8791100B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2531487B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5876419B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102741227B (cg-RX-API-DMAC7.html) |
| AR (1) | AR080102A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2504090T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201130811A (cg-RX-API-DMAC7.html) |
| UY (1) | UY33214A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011095452A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2015129859A1 (ja) * | 2014-02-28 | 2017-03-30 | キッセイ薬品工業株式会社 | 新規なアニリン誘導体、それを含有する医薬組成物およびそれらの用途 |
| CN111548257B (zh) * | 2020-05-28 | 2022-11-15 | 安道麦马克西姆有限公司 | 一种(4-异丙氧基-2-甲基)苯基异丙基酮的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310078B1 (en) * | 1998-04-20 | 2001-10-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
| CN101119714A (zh) * | 2005-02-14 | 2008-02-06 | 弗吉尼亚大学专利基金会 | 含有由氨基和苯基取代的环烷基和5元杂环的1-磷酸鞘氨醇激动剂 |
| CN101407471A (zh) * | 2003-08-29 | 2009-04-15 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| WO1991015583A1 (en) | 1990-04-05 | 1991-10-17 | The American National Red Cross | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| US5869486A (en) * | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
| US6060272A (en) | 1997-05-07 | 2000-05-09 | Human Genome Sciences, Inc. | Human G-protein coupled receptors |
| JP2002531057A (ja) | 1998-08-19 | 2002-09-24 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Edg受容体ファミリーに関連したgタンパク質結合受容体である14274受容体 |
| DE19846979A1 (de) | 1998-09-11 | 2000-03-23 | Max Delbrueck Centrum | G-Protein gekoppelter Rezeptor EDG6 und seine Verwendung |
| NZ510712A (en) | 1998-10-13 | 2004-11-26 | Arena Pharm Inc | Non-endogenous, constitutively activated human G protein-coupled receptors |
| ATE301673T1 (de) | 1998-11-20 | 2005-08-15 | Arena Pharm Inc | Menschliche, an ein g-protein gekoppelter rezeptor rup3 ohne bekannten ligand |
| US6323333B1 (en) | 1999-04-05 | 2001-11-27 | Smithkline Beecham Corporation | Mouse EDG1 |
| WO2001004139A2 (en) | 1999-07-13 | 2001-01-18 | Smithkline Beecham Corporation | Human axor29 receptor |
| GB9923890D0 (en) | 1999-10-08 | 1999-12-08 | Pfizer Ltd | Novel polypeptide |
| WO2001066742A2 (en) | 2000-03-03 | 2001-09-13 | Incyte Genomics, Inc. | G-protein coupled receptors |
| AU4251301A (en) | 2000-03-24 | 2001-10-03 | Bayer Aktiengesellschaft | Regulation of human nerve growth factor-elated g protein-coupled receptor |
| AU2001242800A1 (en) | 2000-03-28 | 2001-10-08 | Takeda Chemical Industries Ltd. | Novel g protein-coupled receptor protein and dna thereof |
| DE60128906T2 (de) | 2000-04-26 | 2008-02-07 | Sanofi-Aventis Deutschland Gmbh | Edg8-rezeptor, dessen herstellung und verwendung |
| DE10028901A1 (de) | 2000-06-10 | 2001-12-20 | Michael Brues | Arminosäuresequenz |
| WO2002006446A2 (en) | 2000-07-17 | 2002-01-24 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the edg6 gene |
| AU2001288563A1 (en) | 2000-08-31 | 2002-03-13 | University Of Connecticut | Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
| CN1253449C (zh) | 2000-11-07 | 2006-04-26 | 诺瓦提斯公司 | 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物 |
| US7521192B2 (en) * | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| CN1592625A (zh) | 2001-08-10 | 2005-03-09 | 惠氏公司 | G蛋白偶联受体测定 |
| DE60329073D1 (de) | 2002-01-18 | 2009-10-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| US20030225288A1 (en) | 2002-04-12 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| EP1523556A1 (en) | 2002-07-18 | 2005-04-20 | Sri International | Methods of treating conditions associated with an edg-1 receptor |
| MXPA05003054A (es) | 2002-09-20 | 2005-05-27 | Pfizer Prod Inc | Ligandos de amida y sulfonamida para el receptor de estrogenos. |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| KR20050084224A (ko) | 2002-12-09 | 2005-08-26 | 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 야누스 티로신 키나제 3을 선택적으로 저해하는 방법 |
| EP1628967B1 (en) | 2003-05-19 | 2014-04-09 | Irm Llc | Immunosuppressant compounds and compositions |
| WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| AU2004268455B2 (en) * | 2003-08-29 | 2009-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| JPWO2005028667A1 (ja) | 2003-09-19 | 2006-11-30 | 独立行政法人理化学研究所 | ヒト肥満細胞で発現するg蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法 |
| EP1524265A1 (en) | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| CN1902171A (zh) * | 2003-11-10 | 2007-01-24 | 舍林股份公司 | 用作ccr-5拮抗剂的苄醚胺化合物 |
| ES2389203T3 (es) | 2004-01-12 | 2012-10-24 | Ym Biosciences Australia Pty Ltd | Inhibidores de quinasa selectivos |
| US20060057559A1 (en) * | 2004-06-23 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | High-throughput cell migration screening assay |
| WO2006014802A2 (en) | 2004-07-27 | 2006-02-09 | Merck & Co., Inc. | Canis sphingosine 1-phosphate receptor isoform 1 |
| EP2384749A1 (en) | 2004-11-29 | 2011-11-09 | Novartis AG | Dosage regimen of an S1P receptor agonist |
| US20090176776A1 (en) | 2005-10-21 | 2009-07-09 | University Of Alabama At Birmingham | Small molecule inhibitors of hiv-1 capsid assembly |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| US7655396B1 (en) * | 2006-09-29 | 2010-02-02 | Allergan, Inc. | Methods for detecting receptor modulator activity |
| US20080108077A1 (en) * | 2006-11-07 | 2008-05-08 | Stephanie Chissoe | Genes associated with rheumatoid arthritis |
| JP2009007341A (ja) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| ATE505454T1 (de) * | 2007-09-20 | 2011-04-15 | Amgen Inc | 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen |
| WO2009053481A1 (en) | 2007-10-25 | 2009-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for modulating nk and t cell trafficking |
| GB0723794D0 (en) | 2007-12-05 | 2008-01-16 | Lectus Therapeutics Ltd | Potassium ion channel modulators and uses thereof |
| UY31631A1 (es) | 2008-02-06 | 2009-09-30 | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
| WO2009103778A1 (en) | 2008-02-19 | 2009-08-27 | Novasaid Ab | Compounds and methods |
| WO2009137081A2 (en) | 2008-05-07 | 2009-11-12 | Massachusetts Institute Of Technology | Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase |
| UY32349A (es) | 2008-12-23 | 2010-07-30 | Novartis Ag | Derivados de biaril-bencil-amina |
-
2011
- 2011-01-28 US US13/015,919 patent/US8791100B2/en active Active
- 2011-01-31 CN CN201180008071.0A patent/CN102741227B/zh not_active Expired - Fee Related
- 2011-01-31 JP JP2012551587A patent/JP5876419B2/ja not_active Expired - Fee Related
- 2011-01-31 WO PCT/EP2011/051296 patent/WO2011095452A1/en not_active Ceased
- 2011-01-31 ES ES11701825.9T patent/ES2504090T3/es active Active
- 2011-01-31 EP EP11701825.9A patent/EP2531487B1/en not_active Not-in-force
- 2011-02-01 AR ARP110100336A patent/AR080102A1/es unknown
- 2011-02-01 TW TW100104005A patent/TW201130811A/zh unknown
- 2011-02-02 UY UY0001033214A patent/UY33214A/es not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310078B1 (en) * | 1998-04-20 | 2001-10-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
| CN101407471A (zh) * | 2003-08-29 | 2009-04-15 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
| CN101119714A (zh) * | 2005-02-14 | 2008-02-06 | 弗吉尼亚大学专利基金会 | 含有由氨基和苯基取代的环烷基和5元杂环的1-磷酸鞘氨醇激动剂 |
Non-Patent Citations (1)
| Title |
|---|
| 1-磷酸鞘氨醇的研究进展;宋士利 等;《中国公共卫生》;20040330;第20卷(第3期);361-363 * |
Also Published As
| Publication number | Publication date |
|---|---|
| UY33214A (es) | 2011-08-31 |
| TW201130811A (en) | 2011-09-16 |
| WO2011095452A1 (en) | 2011-08-11 |
| EP2531487B1 (en) | 2014-06-18 |
| US8791100B2 (en) | 2014-07-29 |
| AR080102A1 (es) | 2012-03-14 |
| EP2531487A1 (en) | 2012-12-12 |
| US20110190258A1 (en) | 2011-08-04 |
| JP5876419B2 (ja) | 2016-03-02 |
| CN102741227A (zh) | 2012-10-17 |
| ES2504090T3 (es) | 2014-10-08 |
| JP2013518846A (ja) | 2013-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI836124B (zh) | 拮抗lpa1受體之脲化合物 | |
| CN103402996B (zh) | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 | |
| JP2022520236A (ja) | 化合物、組成物、及び、方法 | |
| US20210246136A1 (en) | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors | |
| CN104995186B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 | |
| TW201427946A (zh) | 自分泌運動因子(autotaxin)抑制劑 | |
| US20240400547A1 (en) | 2,6-piperidinedione compound and application thereof | |
| CN105829286A (zh) | 作为lta4h抑制剂的杂芳基丁酸衍生物 | |
| CN114450283A (zh) | 3,6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途 | |
| KR20230104191A (ko) | 질환 치료를 위한 이환식 화합물 및 그 용도 | |
| AU2013318779B2 (en) | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same | |
| US20250268903A1 (en) | Rxfp1 agonists | |
| JP2023521237A (ja) | 抗ウイルス1,3-ジ-オキソ-インデン化合物 | |
| TW202333663A (zh) | Rxfp1促效劑 | |
| TW202019406A (zh) | 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法 | |
| US20180271837A1 (en) | Isoxazole carboxamide compounds and uses thereof | |
| EP2531487B1 (en) | Aryl benzylamine compounds | |
| WO2023114456A1 (en) | Uses of bicyclic compounds for the treatment of diseases | |
| WO2025226861A1 (en) | Cyclin inhibitors | |
| HK40122844A (en) | Bicyclic compounds and uses thereof for the treatment of diseases | |
| KR20250030474A (ko) | 화합물, 조성물 및 이의 사용 방법 | |
| HK40113746A (en) | Uses of bicyclic compounds for the treatment of diseases | |
| CN118382441A (zh) | 双环化合物用于治疗疾病的用途 | |
| HK40097563A (en) | Bicyclic compounds and uses thereof for the treatment of diseases | |
| JP2026067760A (ja) | C3a受容体拮抗化合物及びその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel, Switzerland Applicant after: NOVARTIS AG Address before: Basel, Switzerland Applicant before: Novartis AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140730 Termination date: 20220131 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |